Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Synta Cuts Workforce After Suspending Trial

by Rick Mullin
March 23, 2009 | A version of this story appeared in Volume 87, Issue 12

Synta Pharmaceuticals will eliminate 90 positions following the suspension of Phase III clinical trials of elesclomol, a drug it is developing in partnership with GlaxoSmithKline as a treatment for metastatic melanoma. The company claims that the layoffs, which will reduce the total workforce to 130 employees, will allow it to operate with current cash reserves for approximately two more years without additional equity financing. It currently has four other programs in clinical or preclinical development.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.